Navigation Links
Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Date:11/9/2007

- Data Presented at American College of Rheumatology Annual Meeting -

BOSTON, Nov. 9 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that cumulative five-year data from an open-label long-term extension of a Phase IIb trial demonstrate the long-term efficacy and safety of ORENCIA(R) (abatacept) in adult rheumatoid arthritis (RA) patients who had an inadequate response to methotrexate (MTX). The data show that, in these patients, ORENCIA provided sustained improvements in ACR responses, physical function and health-related quality of life. These data, combined with the retention rates observed in this study, demonstrate that ORENCIA provides durable long-term clinical benefits in patients with active RA who had an inadequate response to MTX. Results of this study were presented at the 2007 American College of Rheumatology (ACR) Annual Scientific Meeting.

"Studying the long-term efficacy of a treatment is important because RA is a chronic disease," said Joel Kremer, M.D., Chief of Rheumatology, Albany Medical College. "These data are important because they show that ORENCIA is efficacious and has an acceptable safety profile over an extended period of time in patients with an inadequate response to methotrexate."

Details of the Study

Patients in the initial one-year, double-blind, placebo-controlled randomized trial received MTX and either ORENCIA (10 mg/kg or 2 mg/kg) or placebo administered as a 30-minute intravenous infusion on Days 1, 15 and 30, and every four weeks thereafter, in addition to MTX. The primary endpoint of the double-blind portion of the study was ACR 20 at 6 months (60 percent for ORENCIA(R) (abatacept) vs. 35.5 percent for placebo). All patie
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
5. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
6. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
11. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the Bank ... , , , Date: , , , Wednesday, December ... 2:50 p.m. EST , , , , Location: , , ... About BioScrip, Inc. BioScrip, Inc. ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Aridis ... to produce novel therapies for infectious diseases, announced ... M.D., an internationally recognized key opinion leader in ... Company,s scientific advisory board. Founder and ... stated, "We believe Dr. Opal,s extensive experience investigating ...
(Date:11/26/2014)... CHARLOTTE, N.C. , Nov. 25, 2014  At ... San Antonio this October, KaVo Kerr Group ... Institute Technology Expo, offering attendees the opportunity to see ... to well-respected key opinion leaders deliver lectures on the ... Kerr Group products include the new DEXIS CariVu Caries ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
(Date:11/26/2014)... November 26, 2014 The Deptford ... have launched a partnership designed to improve the ... congestive heart failure (CHF) patients in the South ... and Lourdes Cardiology team will help CHF patients ... protocols. This partnership pairs the Cardiac Recovery program ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Increasing ... stringent drug safety regulations are expected to be ... period. Growing prevalence of acute and chronic ailments ... for new drug development. Moreover, growing adverse drug ... the same has become the need of the ...
(Date:11/26/2014)... 26, 2014 German scientists say carbon-based ... can cause mesothelioma that looks and acts similar to ... article on the research. Click here to read ... for Toxicology and Experimental Medicine in Hannover injected 500 ... of the rats eventually developed mesothelioma , how ...
(Date:11/26/2014)... 26, 2014 The city of San ... is moving forward with a plan to recycle wastewater ... host Sharon Kleyne supports the San Diego plan as ... (TWM). According to Kleyne, by recycling water that San ... water could be greatly reduced. (Spagat, E, “San Diego ...
(Date:11/26/2014)... Loffler Companies has been selected as a 2014 ... information and news publication for resellers of imaging technology, ... Loffler has earned this prestigious award and the seventh ... honor the best and the brightest in the imaging ... chosen for their innovative marketing and sales programs, community ...
Breaking Medicine News(10 mins):Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2
... and more so when its risk looms large. Women who ... risk of developing cervical cancer in the 20 years following ... is one of the major causes of death from cancer ... for cervical cancer, incidence rates and deaths drop significantly. ...
... in the United States, who had voiced vociferous protests ... are now having no such qualms about the introduction ... Merck & Co. and GlaxoSmithKline are still in the ... but concerns had been voiced about them promoting promiscuity ...
... to develop abnormal behaviour, says a study.,Psychologist Seth Pollak ... Wisconsin-Madison studied// 18 four-year-old adoptees, who had spent their ... in a neglected environment. ,Even though the children ... in some cases - they might still display some ...
... and Diabetic Centre at Vasavi Mahal in Chitradurga, ... Dr Narayana Murthy and Dr. Muralidhar conducted the ... ,Dr. Muralidhar is the Principal of Basaveswara Medical ... and treatment to control diabetes is very important ...
... study, published in the November issue of the Journal ... in residential care can reduce their incidence of falls ... years.// ,To determine whether vitamin D supplementation can ... people in residential care who are not classically vitamin ...
... strong risk factor for sudden cardiac death, with the ... ,The authors writing in the October issue of the ... mellitus in industrialized countries is rapidly increasing, and diabetes ... sudden cardiac death. ,The authors examined the ...
Cached Medicine News:Health News:Religious groups overcome objections to cervical cancer vaccines 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: